The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia
Abstract
Background: It has been proposed that schizophrenia is associated with underactivity of brain glutamatergic neurotransmission, especially at the level of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. Glycine potentiates NMDA receptor-mediated neurotransmission, indicating that it may serve as an effective therapeutic agent in the treatment of schizophrenia. Method: Eleven treatment-resistant patients with chronic schizophrenia completed a double-blind placebo-controlled, six-week, randomly assigned, crossover treatment trial of 0.8 g/kg body weight/day of glycine, added to their prior antipsychotic treatment. Results: Glycine was well tolerated, resulted in significantly increased serum glycine levels and induced a mean 36 (7%) reduction in negative symptoms (P < 0.0001). Significant improvments were also induced in depressive and cognitive symptoms. The greatest reduction in negative symptoms was registered in the patients who had the lowest baseline serum glycine levels. Conclusions: These results extend previous findings and suggest an additional approach to the pharmacotherapy of negative symptoms and cognitive deficits in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
(1976) · Medical Entomology and Zoology · Cited by 8,899
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Self-citationBrain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection
Oldendorf, W. (1971) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1971.221.6.1629 · Cited by 1,683
Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
Kim, J. S., Kornhuber, H. H., Schmid-Burgk, W., & Holzmüller, B. (1980) · Neuroscience Letters · doi:10.1016/0304-3940(80)90178-0 · Cited by 694
Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains
Tsai, G. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950220039008 · Cited by 455
Amelioration of negative symptoms in schizophrenia by glycine
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1234 · Cited by 354
Schizophrenia: A Subcortical Neurotransmitter Imbalance Syndrome?
Carlsson, M., & Carlsson, A. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.3.425 · Cited by 341
Five-Factor Model of Schizophrenia Initial Validation
LINDENMAYER, J.-P., BERNSTEIN-HYMAN, R., & GROCHOWSKI, S. (1994) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199411000-00006 · Cited by 258
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1213 · Cited by 243
D-cycloserine added to clozapine for patients with schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1628 · Cited by 182
Hippocampus-dependent learning facilitated by a monoclonal antibody or D-cycloserine
Thompson, L. T., Moskal, J. R., & Disterhoft, J. F. (1992) · Nature · doi:10.1038/359638a0 · Cited by 182
Watson, G. B., Bolanowski, M. A., Baganoff, M. P., Deppeler, C. L., & Lanthorn, T. H. (1990) · Brain Research · doi:10.1016/0006-8993(90)90745-w · Cited by 172
Glycine Adjuvant Therapy to Conventional Neuroleptic Treatment in Schizophrenia
Rosse, R. B., Theut, S. K., Banay‐Schwartz, M., Leighton, M. P., Scarcella, E., Cohen, C. G., & Deutsch, S. I. (1989) · Clinical Neuropharmacology · doi:10.1097/00002826-198910000-00006 · Cited by 101
Glycine Therapy of Schizophrenia
Waziri, R. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90093-5 · Cited by 100
Antagonism of phencyclidine-induced hyperactivity by glycine in mice
Tóth, E., & Lajtha, Á. (1986) · Neurochemical Research · doi:10.1007/bf00965013 · Cited by 95
Leiderman, E. A., Zylberman, I., Zukin, S. R., Cooper, T. B., & Javitt, D. C. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00585-4 · Cited by 92
Self-citationCascella, N. G., Macciardi, F. M., Cavallini, M. C., & Smeraldi, E. (1994) · Journal of Neural Transmission · doi:10.1007/bf01276429 · Cited by 91
Excitatory Amino Acid Receptors in Schizophrenia
Ułas, J., & Cotman, C. W. (1993) · Schizophrenia Bulletin · doi:10.1093/schbul/19.1.105 · Cited by 89
COSTA, J., Khaled, E., Sramek, J. J., Bunney, W. E., & Potkin, S. G. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199002000-00027 · Cited by 57
Glycine Site Agonists of the NMDA Receptor: A Review
D’Souza, D. C., Charney, D. S., & Krystal, J. H. (1995) · CNS Drug Reviews · doi:10.1111/j.1527-3458.1995.tb00285.x · Cited by 56
D-Cycloserine Adjuvant Therapy to Molindone in the Treatment of Schizophrenia
Rosse, R. B., Fay-McCarthy, M., Kendrick, K., Davis, E. R., & Deutsch, S. I. (1996) · Clinical Neuropharmacology · doi:10.1097/00002826-199619050-00008 · Cited by 54
d-Cycloserine therapy of psychosis by symptom provocation
SIMEON, J. G., Fink, M., Itil, T. M., & Ponce, D. E. (1970) · Comprehensive Psychiatry · doi:10.1016/0010-440x(70)90207-5 · Cited by 43
Cited by
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Goff, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 915
Chumakov, I., Blumenfeld, M., Guerassimenko, O., Cavarec, L., Palicio, M., Abderrahim, H., Bougueleret, L., Barry, C., Tanaka, H., La Rosa, P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412499 · Cited by 829
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y.-C., & Chong, M.-Y. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 674
Glutamatergic mechanisms in schizophrenia
Tsai, G., & Coyle, J. T. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.082701.160735 · Cited by 577
Metadata
- Authors
- Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Horowitz, A., & Kelly, D.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 1996-11
- Volume
- 169
- Issue
- 5
- Pages
- 610-617
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2121357459
- Cited by
- 255
- References
- 26
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.